SCNI — Scinai Immunotherapeutics Share Price
Last trade - 00:00- $2.03m
- $14.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -63.98% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- July 22nd, 2003
- Public Since
- June 7th, 2007
- No. of Shareholders
- 13
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,740,770,784
- Address
- Jerusalem Biopark, JERUSALEM, 00000
- Web
- https://www.scinai.com/
- Phone
- +972 89302529
- Contact
- Joshua Phillipson
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for SCNI
Similar to SCNI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:19 UTC, shares in Scinai Immunotherapeutics are trading at $0.47. This share price information is delayed by 15 minutes.
Shares in Scinai Immunotherapeutics last closed at $0.47 and the price had moved by -76.58% over the past 365 days. In terms of relative price strength the Scinai Immunotherapeutics share price has underperformed the S&P500 Index by -80.51% over the past year.
The overall consensus recommendation for Scinai Immunotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Scinai Immunotherapeutics does not currently pay a dividend.
Scinai Immunotherapeutics does not currently pay a dividend.
Scinai Immunotherapeutics does not currently pay a dividend.
To buy shares in Scinai Immunotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.47, shares in Scinai Immunotherapeutics had a market capitalisation of $2.03m.
Here are the trading details for Scinai Immunotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SCNI
Based on an overall assessment of its quality, value and momentum Scinai Immunotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scinai Immunotherapeutics is $39.00. That is 8269.1% above the last closing price of $0.47.
Analysts covering Scinai Immunotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.78 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scinai Immunotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -43.56%.
As of the last closing price of $0.47, shares in Scinai Immunotherapeutics were trading -41.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scinai Immunotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Scinai Immunotherapeutics' directors